Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
Press releases
-
AlzeCure gets late-breaking abstract on NeuroRestore ACD856 clinical data accepted to AD/PD 2022 conference
January 18, 2022
-
AlzeCure holds a digital Capital Markets Day on 18 January
January 12, 2022
-
AlzeCure gets late breaking abstract accepted on NeuroRestore’s positive effect on mitochondrial function
January 11, 2022